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Background: We report levels and determinants of attrition in Rwanda, one of the few African countries with
universal ART access.
Methods: We analyzed data abstracted from health facility records of a nationally representative sample of adults
[≥18 years] who initiated ART 6, 12, and 18 months prior to data collection; and collected facility characteristics
with a health facility assessment questionnaire. Weighted proportions and rates of attrition [loss to follow-up or
death] were calculated, and patient- and health facility-level factors associated with attrition examined using Cox
proportional hazard models.
Results: 1678 adults initiated ART 6, 12 and 18 months prior to data collection, with 1508 person-years [PY] on ART.
Attrition was 6.8% [95% confidence interval [CI] 6.0-7.8]: 2.9% [2.4-3.5] recorded deaths and 3.9% [3.4-4.5] lost to
follow-up. Population attrition rate was 7.5/100PY [6.1-9.3]. Adjusted hazard ratio [aHR] for attrition was 4.2 [3.0-5.7]
among adults enrolled from in-patient wards [vs 2.2 [1.6-3.0] from PMTCT, ref: VCT]. Compared to adults who
initiated ART 18 months earlier, aHR for adults who initiated ART 12 and 6 months earlier was 1.8 [1.3-2.5]
and 1.3 [0.9-1.9] respectively. Male aHR was 1.4 [1.0-1.8]. AHR of adults enrolled at urban health facilities was
1.4 [1.1-1.8, ref: rural health facilities]. AHR for adults with CD4+ ≥200 cells/μL vs <200 cells/μL was 0.8
[0.6-1.0]; and adults attending facilities with performance-based financing since 2004–2006 [vs. 2007–2008]
had aHR 0.8 [0.6-0.9].
Conclusions: Attrition was low in the Rwandan national program. The above patient and facility correlates of
attrition can be the focus of interventions to sustain high retention.
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Millions of HIV-infected adults have initiated antiretro-
viral therapy [ART] in the past decade, but the overall
impact of these programs can be compromised by patient
attrition, including death and loss to follow-up [1-8].
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article, unless otherwise stated.achieved universal ART access, with at least 80% of the
people eligible for ART receiving it [9,10]. ART services in
Rwanda were established in 2002, and by 2012, over
100,000 HIV-infected patients had initiated ART at more
than 400 health facilities [11,12]. High levels of retention
on ART were reported for the first few years of the na-
tional program [13,14]; indeed, in a nationally representa-
tive study conducted in 2004–2005, 92% and 86% of
patients who initiated ART 6 and 12 months earlier, re-
spectively, were alive and on ART at the health facility of
ART initiation [13]. Over time, the national programBioMed Central Ltd. This is an Open Access article distributed under the terms
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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the number of facilities providing ART and the number of
patients initiating ART [12]. As Rwanda, continues to
build sustainable ART programs, it is important to con-
tinually assess whether these high levels of retention can
be sustained with program scale-up and universal ART ac-
cess. We use data from a nationally representative study
of adults initiating ART to report on levels and correlates
of attrition.
Methods
Study design and data collected
The data presented here were collected between September
2008 and April 2009 as part of a nationally-representative
study of adherence among adults on ART. The full
methods have been described elsewhere [15], but briefly
multi-stage sampling was used to select 1,798 adults
who had initiated ARTapproximately 6, 12 and 18 monthsDetermined to be ineligible for this analysis, N
Missing or incomplete data on date of ART initiation
age (n=1), ART regimen (n=1)**
Started ART outside of the pre-specified window,
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Stage 2: Patient selection 
Total Number
Figure 1 Sampling and participant selection. *Data obtained from TRAC
in clinic records at the time of data abstraction.prior to data collection across 20 HIV health facilities
from the total of 9,693 adults receiving ART at 113 health
facilities in Rwanda at the time of sampling (Figure 1).
Data from patient medical charts and pharmacy records—
including demographic and clinical characteristics,
dates of ART initiation and health facility visits, and
patient outcomes—were abstracted by trained study
personnel using a structured tool. A health facility as-
sessment questionnaire captured information on charac-
teristics of each of health facility including the type and
location of the health facility in which HIV services were
located, availability of supportive services for ART patients
e.g. home visits and timing of the introduction of perform-
ance based financing. In this setting, performance based
financing was a supply-side intervention that provided
health facilities a payment mechanism based on fees
for services (conditional on quality) to motivate health
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ber of patients newly initiating ART) were rewarded with
financial incentives and infrastructural support. We hy-
pothesized those facilities that had performance based fi-
nancing for longer would be motivated to ensure better
health outcomes among patients, including retention.
Inclusion criteria
During the study period the national adult ART initi-
ation criteria in Rwanda were CD4 < 200 cells/μL or
WHO stage IV, with stavudine and zidovudine as the
main nucleoside reverse-transcriptase inhibitors used in
first line ART regimens [16]. Patients sampled for the
study described above were eligible for this analysis if
they were 18 years or older, and had initiated first-line
ART at one of the study facilities 6, 12, and 18 months
[+/− 2 months] prior to data collection or transferred
into one of the study facilities within 30 days of ART ini-
tiation. We aimed to determine the population estimate
of attrition by conducting secondary analysis of an exist-
ing dataset, using the entire sample. Basing on Lowrance
et al’s estimates of death and lost to follow-up, we deter-
mined that a dataset of 1798 would allow detection of
attrition between 5% and 7% with >90% power and 5%
precision. Of the 1798 adults originally sampled, 120
were excluded as they started ART outside of the above-
specified timeframe [n = 24], were missing information on
the date of ART initiation [n = 90], ART regimen [n = 1],
and age [n = 1], or transferred to another health facility on
the same day as starting ART [n = 4], resulting in a final
analytic sample of 1678 adults (Figure 1).
Outcome
The outcome for this analysis was attrition, which in-
cluded patients who were known to have died and those
who were lost to follow-up [LTF]. Adults were consid-
ered LTF if they were not known to have died or trans-
ferred to another health facility and had not made a
clinical or pharmacy visit in the 90 days before data ab-
straction. Adults were considered retained on ART if
they picked up ART in the 90 days preceding data ab-
straction. Adults who were recorded as transferring out
to another health facility were reported in a separate
category, and not included in the retained or attrition
outcomes.
Statistical methods
Statistical analysis was conducted using Stata software
version 12.1 [StataCorp. 2011. Stata Statistical Software:
Release 12. College Station, TX: StataCorp LP]. Survey
procedures, including finite population correction, were
used to adjust estimates for the complex survey design.
We applied sampling weights that took into account the
probability of a health facility being selected from the113 health facilities providing ART at the time of sam-
pling and the probability of a participant being selected
from all adults who initiated ART at 6, 12 and 18 months
previously, and thus results presented in this paper rep-
resent population-wide estimates of attrition. Descriptive
statistics were computed for patient- and health facility-
level characteristics. We calculated the proportion and
rates per 100 person years [PY] of attrition for the entire
population and by time on ART [i.e. 6, 12 and 18 months],
and the 95% confidence interval around these estimates.
Adults who transferred to another health facility were
censored at the date of transfer.
Patient- and health facility-level factors associated with
attrition were modeled using weighted data in bivariate
and multivariable Cox proportional hazard models to
calculate crude and adjusted hazard ratios and 95% con-
fidence intervals. Variables included in the model were
pre-selected according to hypothesised relevance and
data availability, excluding variables that were collinear
or lacked heterogeneity. We aggregated adults who had
initiated ART 6, 12, and 18 months prior to data collec-
tion to increase statistical power, and controlled for time
since ART initiation in the multivariable model.
Ethical considerations
The study protocol was approved by the Rwanda National
Ethics Committee and the Institutional Review Board at
Columbia University. This study was funded through the
President’s Emergency Plan for AIDS Relief [PEPFAR]
through the Centers for Disease Control and Prevention
[CDC] and received Associate Director of Science [ADS]
clearance. This analysis was based on data collected
by abstraction from existing medical records; individual-
level patient consent was waived by all approving ethical
boards, and not sought.
Results
A total of 1678 adults were included in this analysis, 644
[37.4%], 578 [33.3%], and 456 [29.3%] who had initiated
ART 6, 12 and 18 months prior to data collection, respect-
ively. The total amount of follow-up time was 1508 person
years, while the average follow-up time was 11.3 months.
The weighted population was 8,373, 3123 [37.3%], 2762
[33.0%], and 2488 [29.7%] patients who had initiated ART
6, 12 and 18 months prior to data collection respectively,
and represented 86.4% of the sampling frame population
of 9,693.
Table 1 shows the characteristics of the population on
ART. Median age of the population at ART initiation was
36 years [IQR 30–43] and 64.6% were female. Over two
thirds [69.0%], were enrolled into the ART program from
voluntary counseling and testing [VCT] services, while
14.6% enrolled from PMTCT services and 4.9% from
in-patient wards. The majority [63.6%] were classified as
Table 1 Patient characteristics: overall distribution and by time on ART










n = 1,678 n = 644 n = 578 n = 456
N Weighted % N Weighted % N Weighted % N Weighted %
Patient-level characteristics
Age groups 18-25 years 200 10.7 61 8.4 76 12.1 63 12.1
26-35 years 619 35.5 229 33.8 210 34.8 180 38.4
36-45 years 562 33.8 227 36.4 185 32.4 150 32.2
46+ years 297 20.0 127 21.5 107 20.7 63 17.3 0.010
Gender Female 1079 64.6 414 64.2 380 65.9 285 63.8
Male 229 35.4 229 35.8 195 34.1 170 36.2 0.361
Source of referral to ART clinic VCTa 1157 69.0 460 70.6 400 68.4 297 67.7
PMTCTb 282 14.6 102 14.6 92 14.1 88 15.2
In-patient ward 70 4.9 21 4.0 20 4.1 29 6.9
Otherc 169 11.5 61 10.8 66 13.4 42 10.2 0.172
WHO stage at ART initiationd Stage I and II 1019 63.6 448 71.7 320 60.5 251 56.8
Stage III 559 32.7 163 25.5 218 35.4 178 39.0
Stage IV 65 3.7 20 2.8 26 4.1 19 4.3 <.001
CD4+ count (cells/μL)
at ART initiation
0 – 199 689 37.1 180 25.7 273 42.1 236 46.0
200 + 753 47.8 357 58.1 236 45.3 160 37.5
Missing 236 15.1 107 16.3 69 12.6 60 16.5 <.001
Initial ART regimen containing… Stavudine 942 58.9 184 34.1 387 65.3 371 83.3 <.001
Zidovudine 731 40.9 459 65.8 188 34.1 84 16.6
Tenofovir 5 0.2 1 0.1 3 0.6 1 0.1
Characteristics of clinic attended
Location Rural 599 50.0 215 47.6 221 53.6 163 49.1
Urban 1079 50.0 429 52.4 357 46.4 293 50.9 0.781
Facility level Health center 914 64.2 349 63.8 326 66 239 62.5
Hospital 764 35.8 295 36.2 252 34 217 37.5 0.928
Facility ownership Faith-based 537 25.3 212 23.0 183 25.6 142 27.7
Public 1141 74.7 432 77.0 395 74.4 314 72.3 0.123
Start of performance based
financing
2004-2006 919 55.2 363 55.7 332 59.0 224 50.1
2007-2008 759 44.9 281 44.3 246 41.0 232 49.9 0.628
Home visits support for PLWHAe 887 50.9 333 49.6 304 52.6 250 50.6 0.942
aVCT = Voluntary Counseling and Testing services; bPMTCT = Prevention of Mother-to-Child HIV Transmission.
cIncludes Tuberculosis clinics [n = 17], outpatient services [n = 45] and other modes of admission [n = 107].
dAdults missing data on WHO stage at ART initiation [n = 35, 2.1%].
ePLWHA = Persons Living with HIV/AIDS.
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2.4% missing WHO stage data at ART initiation. CD4+
counts at ART initiation were available for 84.9% of
the population. Among those with available data, median
CD4+ count was 206 cells/μL [IQR 137–286], and 37.0%
had CD4+ count less than 200cells/μL at the time of ART
initiation. Of note, the median CD4 count at ART initi-
ation among adults who started ART as in-patients was 74
cells/μL [IQR 34–194] vs 218 cells/μL [IQR 150–288]among patients enrolled from VCT and 256 cells/μL [IQR
177–313] among patients enrolled from PMTCT clinics.
The majority of the population initiated stavudine [58.9%]
and zidovudine [40.9%] in the first-line regimen, all
combined with lamivudine and nevirapine [90.3%] or
efavirenz [9.1%].
Half the population attended health facilities located in
rural areas [50.0%], and the majority attended health cen-
ters [64.2%, vs 35.8% at hospitals]; and public government
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ities]. All health facilities had performance based finan-
cing Nearly half [44.9%] of the population attended health
facilities where performance based financing had been
introduced more recently [2007–2008 vs. 2004–2006]
and half attended health facilities where home visit
support services for patients who miss health facility
visits were available [50.9%].
When comparing the population by time of ART initi-
ation, the population who initiated ART 6 and 12 months
prior to data collection had a higher proportion of older
adults [36 years and older], adults with WHO Stage I
and II at ART initiation, and adults with CD4+ count
above 200 cells/μL at ART initiation, than the popula-
tion who initiated ART 18 months prior to data collec-
tion. Stavudine use in the initial ART regimen declined
from 83.3% to 65.3% and 34.1% for adults who had initi-
ated ART 18, 12 and 6 months previously, while zidovu-
dine use increased from 16.6% to 34.1% and to 65.8%
respectively.
Of the population that initiated ART, 5.5% transferred
out to other health facilities. Of the remaining population,
attrition was observed among 6.8%, with 2.9% docu-
mented to have died and 3.9% lost to follow-up [Table 2].
Attrition among adults who had initiated ART 6, 12 and
18 previously was 3.5%, 8.8% and 8.8% respectively. The
population attrition rate was 7.5/100 PY, with deaths ac-
counting for 3.2/100 PY and loss to follow-up 4.3/100PY
[Table 2]. Attrition rates among adults who had initiated
ART 6, 12 and 18 previously were 6.9/100 PY, 9.1/100 PY
and 6.4/100 PY respectively.
Table 3 displays patient- and health facility-level char-
acteristics associated with attrition in the bivariate and
multi-variable analyses adjusting for various demographic,
clinical and site characteristics. The adjusted hazard ratio
[aHR] for attrition was highest for adults enrolled from
in-patient wards: aHR 4.2 [95% CI: 3.0-5.7]; and PMTCT
services: aHR 2.2 [95% CI: 1.6-3.0], compared to those en-
rolled from VCT services. Compared to adults who initi-
ated ART 18 months earlier, adults who initiated ART
12 months earlier had higher hazard of attrition: aHR 1.8
[95% CI: 1.3-2.5]; but no significant difference was ob-
served with adults who had initiated ART in the previous
6 months: aHR 1.3 [95% CI: 0.9 – 1.9]. A higher hazard of
attrition was also observed among men: aHR 1.4 [95% CI:
1.0-1.8] than women; and adults attending urban health
facilities: aHR 1.4 [95% CI: 1.1-1.8] compared to those at-
tending rural facilities.
The hazard of attrition was lower among adults whose
CD4+ count at ART initiation was 200 cells/μL or greater,
aHR 0.8 [95% CI: 0.6-1.0], compared to those who initiated
ART with CD4+ counts below 200 cells/μL. Lower attri-
tion hazard was also observed among adults who attended
health facilities that had longer-standing performance-based financing [since 2004–2006], aHR 0.8 [95% CI:
0.6-0.9], compared to patients attending health facilities
where performance based financing had began more re-
cently [2007–2008]. Age, initial ART regimen, level of health
facility and availability of home visit services were not sig-
nificantly associated with attrition in adjusted analyses.
Discussion
We assessed levels of attrition 6, 12 and 18 months fol-
lowing ART initiation among a nationally representative
sample of adults receiving HIV services in Rwanda. We
estimated overall population attrition to be 6.8% and the
attrition rate as 7.5/100 PY. Lowrance et al., who explored
this question in the early phase of the Rwanda ART pro-
gram [2004–2005], reported attrition of 6.7% of patients
at 6 months and 9.5% at 12 months on ART [13]. We
found much lower attrition at 6 months, 3.5%, and ap-
proximately the same attrition at 12 months, 8.8%, in
2007–2008, suggesting a significant reduction in attrition
at the 6 months following ART initiation. Our results tally
with more recent findings using a significantly larger sam-
ple in two regions of Rwanda [17]. This is an important
finding because the risk of attrition tends to be highest
immediately after ART initiation, and is usually due to
high mortality within this time period [18-20]. These find-
ings may reflect the benefits of initiating ART earlier in
HIV disease, as the median CD4+ count at ART initiation
in our sample was 65 cells/μL, higher than that observed
by Lowrance et al.
While Lowrance et al. observed that death and LTF
contributed equally to attrition in the early phase of
ART scale-up in Rwanda, our data indicate that LTF in-
creasingly accounts for the majority of attrition. This
may reflect deteriorating ascertainment and documenta-
tion of deaths as the ART program expands, and an in-
crease in undocumented transfers as ART services are
decentralized [20-22]. Stronger linkages and feedback
between communities and health facilities [to report
deaths] and between health facilities [to report transfers]
could result in more accurate estimations of true loss to
follow-up, mortality, and transfers and thus more
complete assessment of the ART program impact.
While the level of attrition observed in our sample was
in-line with other findings from Rwanda [13,14,23,17], it is
substantially lower than that observed in other programs
within the East African region, which report attrition in
the range of 18% to 40% 12 months after ART initiation
[24-28]. Multiple factors may be contributing to the low
attrition in ART programs in Rwanda. First, the median
CD4+ count at ART initiation in our population was sig-
nificantly higher than has been observed in other coun-
tries [18,25,29,30], and could account for this association.
Our results also showed that CD4+ counts >200/μL were
associated with a 20% reduction in attrition. Notably,
Table 2 Proportion and rate of attrition and transfers per 100 person years: overall and by time on ART
Time on ART prior to data collection
Overall (all adults) 6 months on ART 12 months on ART 18 months on ART
1509 person years 330 person years 559 person years 619 person years
1678 adults 644 adults 578 adults 456 adults
Proportions: n Weighted % 95% CI n Weighted % 95% CI n Weighted % 95% CI n Weighted % 95% CI
Attrition 135 6.8 [6.0 – 7.8] 25 3.5 [2.7 – 4.5] 58 8.8 [7.1 – 10.9] 52 8.8 [7.9 – 11.4]
Recorded death 48 2.9 [2.4 – 3.5] 13 1.6 [1.1 – 2.3] 16 2.9 [2.0– 4.1] 19 4.6 [3.5 – 6.0]
Lost to follow-up 87 3.9 [3.4 – 4.5] 12 1.9 [1.3 – 2.7] 42 5.9 [5.0 – 7.0] 33 4.2 [3.2 – 5.6]
Transfer out 99 5.5 [4.5 – 6.8] 34 6.1 [4.5 – 8.2] 26 3.6 [2.5 – 5.3] 39 6.9 [4.8 – 9.8]
Retained on ART 1444 87.7 [86.0 – 89.2] 585 90.4 [88.4 – 92.2] 494 87.6 [84.7 – 90.0] 365 84.3 [80.4 – 87.5]
Rates: No. Weighted rate 95% CI No. Weighted rate 95% CI No. Weighted rate 95% CI No. Weighted rate 95% CI
Attrition 135 7.5 [6.1 – 9.3] 25 6.9 [4.3 – 11.9] 58 9.1 [6.6 – 12.7] 52 6.4 [4.6 – 9.2]
Recorded death 48 3.2 [2.3 – 4.5] 13 3.2 [1.7 – 6.9] 16 2.9 [1.6 – 5.6] 19 3.3 [2.0 – 5.9]
Lost to follow-up 87 4.3 [3.3 – 5.6] 12 3.7 [1.8 – 8.8] 42 6.1 [4.2 – 9.2] 33 3.1 [2.0 – 4.9]
Transfer out 99 6.0 [4.7 – 7.8] 34 12.1 [7.9 – 19.4] 26 3.7 [2.4 – 6.3] 39 5.0 [3.4 – 7.5]
Retained on ART 1444 95.7 [92.8 – 98.7] 585 179.5 [174.5 – 184.6] 494 90.3 [88.1 – 92.6] 365 61.1 [59.5 – 62.7]






















Table 3 Crude and adjusted Cox proportional models for the hazard of attrition (death or loss to follow-up)
Bivariate analysis Multi-variable model n = 1,678
Attrition N HR of attrition 95% CI p-value aHR of attrition 95% CI p-value
Time on ART prior to data collection
18 months on ART 52 Ref Ref
6 months on ART 25 1.1 [0.8 – 1.7] 0.517 1.3 [0.9 - 1.9] 0.190
12 months on ART 58 1.7 [1.2 - 2.4] 0.003 1.8 [1.3 - 2.5] 0.000
Age
18-25 years 27 Ref Ref
26-35 years 48 0.8 [0.5 - 1.2] 0.195 0.8 [0.5 - 1.3] 0.395
36-45 years 44 0.9 [0.6 - 1.2] 0.318 1.0 [0.7 - 1.4] 0.864
46+ years 16 0.6 [0.4 - 0.9] 0.014 0.8 [0.5 - 1.3] 0.379
Gender
Females 48 Ref Ref
Males 87 1.3 [1.0 - 1.6] 0.066 1.4 [1.0 - 1.8] 0.027
Source of referral to ART clinic
Voluntary Counseling and Testing 70 Ref Ref
PMTCT services 35 2.1 [1.6 - 2.7] 0.000 2.2 [1.6 - 3.0] 0.000
In-patient ward 15 4.1 [3.0 - 5.6] 0.000 4.2 [3.0 - 5.7] 0.000
Other 15 1.6 [1.2 - 2.2] 0.001 1.5 [1.1 - 2.0] 0.004
CD4+ count at ART initiation (cells/μL)
0 – 199 69 Ref Ref
200+ 45 0.7 [0.5 - 0.9] 0.005 0.8 [0.6 - 1.0] 0.031
Missing 21 1.0 [0.7 - 1.3] 0.763 1.0 [0.8 - 1.3] 0.811
Initial ART regimen
Stavudine containing 80 Ref Ref
Zidovudine containing 54 1.1 [0.9 - 1.3] 0.423 1.0 [0.8 - 1.2] 0.944
Tenofovir containing 1 1.6 [0.7 - 3.6] 0.240 1.7 [0.8 - 3.9] 0.165
Location
Rural 32 Ref Ref
Urban 103 1.5 [1.1 - 2.0] 0.005 1.4 [1.1 - 1.8] 0.013
Facility level*
Hospitals 52 Ref Ref
Health centers 83 0.9 [0.7 - 1.2] 0.483 0.8 [0.6 - 1.1] 0.226
Start of performance based financing
2007-2008 85 Ref Ref
2004-2006 50 0.9 [0.6 - 1.2] 0.239 0.8 [0.6 - 0.9] 0.016
Home support visits for PLWHA available
No 60 Ref Ref
Yes 75 1.2 [0.9 - 1.6] 0.415 1.2 [1.0 - 1.6] 0.097
*Facility ownership variable (public vs faith based) excluded from the model due to collinearity with facility level variable.
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ing had similar hazard of attrition to the patients with the
lowest CD4+ counts. This finding suggests that patients
whose CD4+ counts are not assessed and recorded at
ART initiation may be as vulnerable to attrition as the
sickest patients. Secondly, adults in the Rwanda ARTprogram tend to have high adherence to ART [31,32]
which in turn can reduce mortality, and thus attrition.
This is further evidenced by adherence and viral load as-
sessments conducted on a subset of participants in this
analysis which revealed that overall [combining adults on
ART 6, 12 and 18 months], 94% and 78% took 100% of
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view, and 83% had viral load under 40 copies/mL at the
time of interview [15].
The most significant factor associated with increased
hazard of attrition in our study was starting ART while
admitted within an in-patient ward. This finding has
been observed by others [33], and is likely due to high
mortality in this severely ill group and LTF due to un-
documented deaths [20,34]. Indeed, the median CD4
count at ART initiation among in-patients was about a
third of observed among other study participants. Recent
recommendations by WHO and the Rwanda Ministry of
Health [35-37], which endorse ART initiation at higher
CD4 counts [350 cells/μ/L and more recently 500 cells/
μ/L], could result in adults initiating ART earlier in HIV
disease, and thus lower attrition. Enrolling from PMTCT
services was also associated with high attrition. This has
been observed in a number of African programs [38,39],
and is a challenge worth addressing as countries begin to
implement for life-long ART for all pregnant and breast-
feeding women. The finding that men had higher attrition
than women is not uncommon in African HIV treatment
programs [40-44]; this is a high risk group that requires
targeted interventions to minimize attrition.
Adults who attended health facilities with a longer
duration of performance based financing had a lower
hazard attrition in our analysis. Although our analysis
lacked data to comparatively examine attrition at facili-
tates without performance based financing, implementa-
tion of performance based financing is perceived as a
strong motivator for provision of better health care ser-
vices [45-47], and may have contributed to improvements
in patient outcomes at these health facilities clinics. It is
possible that sites that initiated performance based finan-
cing earlier had other unmeasured characteristics that in-
fluenced attrition outcomes, and further research should
examine the specific impact of this strategy on lowering
attrition in African ART programs.
Our study did not find a correlation between home
visits and attrition, a finding in line with results of a
multi-country ecological study examining the impact of
site-level factors on attrition [48]. Whereas it has been
observed that home-visits can be associated with better
retention [49], it is likely that in our setting of high re-
tention, the impact of home visits was minimal, particu-
larly if targeted to patients with high risk of attrition
that may have insurmountable barriers to returning to
care.
Our study had a number of strengths. We had a large
sample of adults drawn from a nationally representative
sample of adults on ART, and there was representation
from different types of health facilities in various set-
tings. The study was conducted in one of the first few
African countries to achieve universal ART access. Inmultivariate analyses, we explored associations between
both patient- and health facility- level factors and attri-
tion. A limitation to note, however, is that the study
lacked sufficient power to examine factors associated
with death and LTF in separate models or present results
stratified by time on ART. Despite this, the results ef-
fectively demonstrate the low attrition rates and some
key factors associated with the risk of attrition for the
overall population.
Conclusion
Our results suggest sustained low attrition in the Rwanda
national ART program in the context of significant expan-
sion in the number of clinics providing HIV care and
treatment services and the number of patients on ART.
Loss to follow-up was the more significant contributor to
attrition suggesting that better ascertainment and docu-
mentation of deaths and patient transfers may be neces-
sary. In this context of universal ART access, specific
groups remain at risk of high attrition [including in-
patients, men, PMTCT clients and adults attending urban
facilities] and require targeted interventions to further re-
duce attrition. Performance-based financing could be a
useful tool in minimizing attrition in this context.
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